Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

Exclusion Criteria

• •Metastatic disease.
• •Previous surgical, radiotherapy and/or chemotherapy treatment for the disease in the study.
• •Other non-oropharyngeal tumour sites in the head and neck area.
• •Other previous and/or simultaneous squamous cell carcinoma.
• •Diagnosis of any other cancer in the previous 5 years, except properly treated carcinoma in situ of the uterine cervix and/or basal cell skin carcinoma.
• •Active infection (infection requiring intravenous antibiotics), including active tuberculosis and diagnosed HIV.
• •Uncontrolled hypertension defined as systolic blood pressure \>= 180 mm Hg and/or diastolic blood pressure \>= 130 mm Hg at rest.
• •Pregnancy (absence of pregnancy must be confirmed with the serum-HCG test) or breast-feeding women.
• •Chronic, concomitant systemic immunotherapy, or hormonal treatment for the cancer.
• •Other concomitant anti-cancer treatments.
• •Clinically significant coronary artery disease, history of myocardial infarction in the previous 12 months or high risk of out of control arrhythmia or cardiac insufficiency.
• •Chronic obstructive pulmonary disease which may have required \> 3 hospitalisations in the previous 12 months.
• •Out of control active peptic ulcer.
• •Presence of a psychological or medical illness which might impede the patient from carrying out the study or giving his or her signature on the informed consent
• •Known drug abuse (with the exception of excessive alcohol consumption)
• •Known allergic reaction to any of the components of the treatment to be studied.
• •Previous treatment with monoclonal antibodies or signal transduction inhibitors or other EGFR-targeted treatment.
• •Any experimental treatment in the 30 days prior to enrolment in the study.